Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Approval symbols : Arct save search
Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
Published: 2023-01-31 (Crawled : 14:00) - biospace.com/
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
|
| O: 0.1%
H: 4.14%
C: 4.14%
arct-032 fibrosis application trial approval therapeutics cystic fibrosis
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-10-12 (Crawled : 13:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.21%
H: 0.14%
C: -1.05%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.16%
H: 0.11%
C: -1.44%
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
|
| O: 4.89%
H: 1.6%
C: -1.84%
vaccine phase 3 approval sars-cov-2
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-09-22 (Crawled : 12:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: -1.11%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.5%
H: 0.36%
C: -0.86%
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
|
| O: 1.81%
H: 2.1%
C: -0.32%
phase 2 vaccine phase 3 approval sars-cov-2
Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study
Published: 2021-08-03 (Crawled : 12:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: -0.6%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.27%
H: 1.02%
C: 0.96%
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
|
| O: 13.79%
H: 51.6%
C: 47.69%
phase 1 vaccine trial approval sars-cov-2
Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-08-02 (Crawled : 14:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -0.36%
H: 0.75%
C: -0.18%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.02%
H: 0.21%
C: -0.12%
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
|
| O: 6.36%
H: 9.92%
C: 5.16%
vaccine trial approval sars-cov-2
Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
Published: 2021-07-28 (Crawled : 15:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.42%
H: 2.14%
C: 1.72%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.04%
H: 0.38%
C: -0.32%
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
|
| O: -0.19%
H: 6.93%
C: 6.54%
phase 2 approval
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.